Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer

Oral Oncology

Volumn 49, Issue 7, 2013, Pages 707-710

  Sherman, Steven I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Kinase inhibitors; Medullary thyroid carcinoma; RET

Indexed keywords

CABOZANTINIB; CALCITONIN; MOTESANIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; VANDETANIB; VASCULOTROPIN RECEPTOR;

ALLELIC IMBALANCE; ARTICLE; AUTOPHOSPHORYLATION; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; DISTANT METASTASIS; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; METASTASIS; MULTICENTER STUDY (TOPIC); ONCOGENE RET; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 84879123347     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.03.442     Document Type: Article

References (32)

1. S.Y. Boostrom, C.S. Grant, G.B. Thompson, D.R. Farley, M.L. Richards, and T.L. Hoskin Need for a revised staging consensus in medullary thyroid carcinoma Arch Surg 144 7 2009 663 669
2. D.W. Ball Medullary thyroid cancer: monitoring and therapy Endocrinol Metab Clin North Am 36 3 2007 823 837
3. L.M. Mulligan, J.B. Kwok, C.S. Healey, M.J. Elsdon, C. Eng, and E. Gardner Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363 6428 1993 458 460
4. H. Donis-Keller, S. Dou, D. Chi, K.M. Carlson, K. Toshima, and T.C. Lairmore Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC Hum Mol Genet 2 7 1993 851 856
5. M. Santoro, F. Carlomagno, A. Romano, D.P. Bottaro, N.A. Dathan, and M. Grieco Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B Science 267 5196 1995 381 383
6. R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini, and E. Molinaro Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study J Clin Endocrinol Metab 93 3 2008 682 687
7. W. Pao, and K.E. Hutchinson Chipping away at the lung cancer genome Nat Med 18 3 2012 349 351
8. L. Santarpia, and G. Bottai Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers Curr Pharm Des 19 2013 864 882
9. R. Parthasarathy, G.J. Cote, and R.F. Gagel Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma Cancer Res 59 16 1999 3911 3914
10. F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, and G. Vecchio ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 2002 7284 7290
11. V. Johanson, H. Ahlman, P. Bernhardt, S. Jansson, L. Kolby, and F. Persson A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis Endocr Relat Cancer 14 2 2007 433 444
12. D. Vitagliano, V. De Falco, A. Tamburrino, S. Coluzzi, G. Troncone, and G. Chiappetta The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells Endocr Relat Cancer 18 1 2011 1 11
13. S.A. Wells Jr., J.E. Gosnell, R.F. Gagel, J. Moley, D. Pfister, and J.A. Sosa Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer J Clin Oncol 28 5 2010 767 772
14. N. Akeno-Stuart, M. Croyle, J.A. Knauf, R. Malaguarnera, D. Vitagliano, and M. Santoro The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells Cancer Res 67 14 2007 6956 6964
15. B.G. Robinson, L. Paz-Ares, A. Krebs, J. Vasselli, and R. Haddad Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer J Clin Endocrinol Metab 95 6 2010 2664 2671
16. S.A. Wells Jr., B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, and M. Santoro Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol 30 2 2012 134 141
17. F.M. Yakes, J. Chen, J. Tan, K. Yamaguchi, Y. Shi, and P. Yu Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 12 2011 2298 2308
18. R. Kurzrock, S.I. Sherman, D. Ball, A.A. Forastiere, R.B. Cohen, and R. Mehra Activity of XL184, an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer J Clin Oncol 29 19 2011 2660 2666
19. P. Schoffski, R. Elisei, S. Muller, M.S. Brose, M.H. Shah, and L.F. Licitra An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline J Clin Oncol 30 15 2012 5508
20. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid; 2012.
21. A. Boichard, L. Croux, A. Al Ghuzlan, S. Broutin, C. Dupuy, and S. Leboulleux Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon J Clin Endocrinol Metab 97 10 2012 E2031 2035
22. C. Rodriguez-Antona, J. Pallares, C. Montero-Conde, L. Inglada-Perez, E. Castelblanco, and I. Landa Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis Endocr Relat Cancer 17 1 2010 7 16
23. C. Capp, S.M. Wajner, D.R. Siqueira, B.A. Brasil, L. Meurer, and A.L. Maia Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma Thyroid 20 8 2010 863 871
24. M. Papotti, M. Olivero, M. Volante, F. Negro, M. Prat, and P.M. Comoglio Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid Endocr Pathol 11 1 2000 19 30
25. Caprelsa Prescribing Information. < http://www1.astrazeneca-us.com/pi/ caprelsa.pdf >. [accessed 30.01.13].
26. Cometriq Full Prescribing Information. < http://www.cometriq.com/ downloads/Cometriq-Full-Prescribing-Information.pdf >. [accessed30.01.13].
27. A.A. Carhill, M.E. Cabanillas, C. Jimenez, S.G. Waguespack, M.A. Habra, and M. Hu The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring J Clin Endocrinol Metab 98 1 2013 31 42
28. M. Schlumberger, R. Elisei, L. Bastholt, L.J. Wirth, R.G. Martins, and L. Locati Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer J Clin Oncol 27 23 2009 3794 3801
29. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, and P. Pochanard Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 22 2011 3085 3096
30. E. Vergani, V. Vallacchi, S. Frigerio, P. Deho, P. Mondellini, and P. Perego Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032 Neoplasia 13 12 2012 1132 1142
31. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, and D. Zecchin Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 7387 2012 100 103
32. A.C. Dar, T.K. Das, K.M. Shokat, and R.L. Cagan Chemical genetic discovery of targets and anti-targets for cancer polypharmacology Nature 486 7401 2012 80 84